EBR Systems Signs Agreement with Advocate Health for WiSE System

Major US Health System Opens Pathway for WiSE Adoption

EBR Systems (ASX:EBR) has secured a purchasing agreement with Advocate Health, the third-largest non-profit integrated health system in the United States. This deal covers 69 hospitals across eight states, including Alabama, Georgia, Illinois, Indiana, Michigan, North Carolina, South Carolina, and Wisconsin. The agreement establishes a formal purchasing pathway for EBR’s WiSE System, a wireless cardiac pacing device designed to stimulate the heart’s left ventricle without traditional leads.

Advocate Health’s scale and integrated structure make it a significant commercial partner for EBR as it pushes deeper into the US market. The arrangement allows EBR to engage directly with physicians within Advocate’s network to bring the WiSE System to patients requiring cardiac resynchronisation therapy (CRT). The company expects this to support broader hospital access over time, potentially accelerating adoption within one of the country’s largest non-profit health systems.

WiSE Technology Offers Leadless Pacing Advantage

EBR’s WiSE technology is unique in offering wireless, endocardial pacing of the left ventricle, a location considered more anatomically effective than traditional pacing sites. The implant is roughly the size of a grain of rice and eliminates the need for coronary sinus leads, which have historically caused complications and reliability issues in CRT patients. Currently, WiSE is available for sale only in the US and remains investigational elsewhere.

CEO John McCutcheon described the agreement as an important commercial milestone, highlighting its role in building momentum for the ongoing US rollout. This follows recent quarterly reports showing increased implant volumes and revenue growth, with Q1 2026 revenue reaching US$2.4 million amid an accelerated commercial rollout phase. The company’s expanding footprint and regulatory progress, including a TGA Priority Review in Australia, suggest a multi-market growth strategy underway.

Commercial Momentum and Uncertain Financial Details

While the agreement with Advocate Health is a strategic win, the announcement does not disclose financial terms or specific timelines for implementation. Forward-looking statements caution that risks and uncertainties remain, including the pace of clinical adoption and regulatory approvals. Investors will note this deal builds on a series of recent commercial advances, including doubling implant volumes and securing multiple purchase agreements earlier in 2026.

EBR’s US commercial rollout has gained traction since FDA approval in 2025, with revenue climbing but losses widening due to increased cash burn. The company recently completed a one-for-ten reverse stock split to restructure equity, reflecting ongoing efforts to stabilise its capital base as it scales. The Advocate Health agreement adds a significant channel to access a large patient population but leaves open questions about how quickly this will translate into revenue growth.